RUNX2 and acute myeloid leukemia: Five structurally distinct GSK3 inhibitors (Fig. 2a) led to dose-dependent enhancement of NK cell activity against an AML cell line, OCI-AML3 and primary AML patient samples (Fig. 2b and Supplementary Fig. 2).